Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Participants With Systemic Sclerosis

NCT05462522 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT05462522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05462522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Participants With Systemic Sclerosis
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 16, 2023
Completion date
July 11, 2025
Enrollment
56 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis